Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

The drug is the first injectable CD20xCD3 bispecific antibody to be approved in this setting, providing a subcutaneously administered alternative to Roche’s intravenous infusion Columvi ...

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer patients treated with Nubeqa plus ADT experienced a clinically meaningful ...

Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 14% SPDR S&P 500 UCITS ETF - USD DIS 13% iShares Core S&P 500 UCITS ETF - USD ACC 13% ...